Biosimilars: After FDA's Public Meeting, Is A Payer Summit Needed Too?
Executive Summary
FDA may be forced to campaign for support of its biosimilar decisions in the health care community to ensure entities like hospital Pharmacy and Therapeutics Committees embrace the products.
You may also be interested in...
NPC’s Attempt To Lift Veil Of Secrecy From Formulary Decisions Fails
A real-world pilot test of a National Pharmaceutical Council/Cerner Research tool designed to bring clarity, consistency and transparency to formulary decisions made by private payers’ pharmacy and therapeutics committees fails to offer any insight on those decisions.
Biosimilar Application Pathway Likely To Travel Through Courts
The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.
Biosimilar Application Pathway Likely To Travel Through Courts
The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.